Design Therapeutics, Inc. (DSGN)
| Market Cap | 891.20M |
| Revenue (ttm) | 53,000 |
| Net Income (ttm) | n/a |
| Shares Out | 55.08M |
| EPS (ttm) | -0.91 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 135,189 |
| Open | 15.95 |
| Previous Close | 15.98 |
| Day's Range | 15.35 - 17.03 |
| 52-Week Range | 13.93 - 50.50 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 34.67 (+114.4%) |
| Est. Earnings Date | Nov 8, 2021 |
About DSGN
Design Therapeutics is a preclinical-stage biopharmaceutical company pioneering novel small-molecule therapeutic candidates, called gene targeted chimeras (GeneTACs), that are designed to be disease-modifying and target the underlying cause of inherited nucleotide repeat expansion diseases, of which there are more than 40 debilitating degenerative diseases. Individuals with nucleotide repeat expansion diseases are born with abnormally expanded stretches of specific nucleotide sequences, often with hundreds to thousands of excess repeats present...
Financial Performance
In 2020, DSGN's revenue was $226,000, a decrease of -72.90% compared to the previous year's $834,000. Losses were -$8.28 million, 304.5% more than in 2019.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for DSGN stock is "Buy." The 12-month stock price forecast is 34.67, which is an increase of 114.41% from the latest price.
News
Design Therapeutics Announces Positive Preclinical Data Highlighting Disease-Modifying Potential of its Novel DM1 Gen...
Data to be Presented during the 2021 Virtual Myotonic Dystrophy Foundation Annual Conference Data to be Presented during the 2021 Virtual Myotonic Dystrophy Foundation Annual Conference
4 Stocks Insiders Are Buying
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.
Design Therapeutics Reports GeneTAC™ Portfolio Progress and Second Quarter 2021 Results
Preclinical Data Support Initiation of Clinical Development of Lead GeneTAC Program for Friedreich Ataxia in the First Half of 2022
Design Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference
CARLSBAD, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today reported that João S...
Design Therapeutics Expands Board of Directors with Key Appointments
CARLSBAD, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today announced the appoin...
Design Therapeutics Announces Business Highlights and Reports First Quarter 2021 Financial Results
Successful $276 Million IPO Completed to Advance GeneTAC TM Programs for Friedreich Ataxia and Myotonic Dystrophy Type-1 Toward Clinical Development
Design Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchas...
CARLSBAD, Calif., March 30, 2021 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN) (“Design”), a biotechnology company developing a platform of gene targeted chimera (GeneTAC™) small molecule...
Design Therapeutics Announces Pricing of Initial Public Offering
CARLSBAD, Calif., March 25, 2021 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc., a biotechnology company developing a platform of gene targeted chimera (GeneTAC™) small molecules for the treatment of ser...
Preclinical autoimmune disease biotech Design Therapeutics files for a $100 million IPO
Design Therapeutics, a preclinical biotech developing gene targeted chimeras for nucleotide expansion diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Design Therapeutics IPO Registration Document (S-1)
Design Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.